Dr. Walter is currently VP of Regulatory Affairs at Acorda Therapeutics with primary responsibility for the global regulatory affairs strategy and operations.
Dr. Walter brings over 25 years of experience in the pharmaceutical industry, including 16 years in Global Regulatory Affairs. Dr. Walter has a successful track record in leading small molecule and biologics products from early development to approval in the fields of neurology, cardiovascular, pulmonary, and immune-based diseases guiding several orphan drug and priority review applications and recently the advisory committee for Ampyra (dalfampridine) ER tablets in multiple sclerosis securing its marketing approval.
Prior to joining Acorda, Dr. Walter held various positions of increasing responsibilities in Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals and scientific positions in Drug Metabolism and Clinical Pharmacokinetics at Boehringer Ingelheim and Ciba Geigy (currently Novartis) . Dr. Walter has a Ph.D. in Toxicology with emphasis on drug metabolism from the College of Pharmacy at University of Kentucky, Lexington, KY and a B.S. in Biology from Denison University, Granville, OH.